Gilead’s long-serving Norbert Bischofberger, Ph.D., is stepping down as EVP of R&D and chief scientific officer this April, as the company promotes John McHutchison, M.D., to the top job.
McHutchison, currently EVP of clinical research, will become CSO while taking over the company’s R&D org from Bischofberger next month.
This has also caused a domino effect for others at the company. Andrew Cheng, M.D., Ph.D., EVP of clinical research and ops, will become Gilead’s CMO, with both reporting to John Milligan, Ph.D., Gilead’s president and chief.
Bischofberger, who started at Gilead in 1990 and became CSO 11 years ago, will leave the company completely in July.
There was no talk of retirement, or why Bischofberger had decided to leave, but Milligan said he and the company “wish him all the best in the next phase of his professional career,” meaning he’s likely to pop up somewhere else soon.
McHutchison has been at Gilead since 2010, coming from Duke University Medical Center, and started out as Gilead’s SVP of liver disease therapeutics. Cheng, meanwhile, has been at the company since 1999, leading its HIV/AIDS programs.
In his new CMO role, Cheng will “retain leadership of the company’s HIV clinical research program and will assume responsibility for Gilead’s medical affairs organization,” as Gilead gears up its HIV/AIDS pipeline, something that has analysts excited for its prospects.
Gilead’s big new prospect, of course, will be its CAR-T program coming out of its $12 billion deal for Kite Pharma last year, and its CAR-T 2.0 attempts with its much cheaper buyout of Cell Design Labs in December.
By Ben Adams
Source: Fierce Biotech
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.